Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.76 (2.20%)
Data as of 09/19/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
08/30/17The Medicines Company Announces FDA Approval of VABOMERE™ (meropenem and vaborbactam)
–Accelerated approval for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis– –First carbapenem-based combination product – combination of meropenem with a new class of beta-lactamase inhibitor– –Addresses pathogens designated by the CDC as urgent and serious antimicrobial resistance threats, and pathogens cited by the WHO as a critical need for new antibiotics– –VABOMERE exp... 
Printer Friendly Version
08/28/17New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials
–Inclisiran lowering effects on bad-cholesterol (LDL-C) are robust (mean 56% at Day-150; maximum 81%) and sustained (average 51% across a planned six-month dosing interval), with minimum intra-patient variability– –Safety data for inclisiran from ORION-1 now include 370 subject-years of observation, including at least 300 subject-years of inclisiran effects; no material safety issues observed on inclisiran – similar to placebo– ... 
Printer Friendly Version
08/09/17The Medicines Company Reports Second Quarter 2017 Business and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 9, 2017-- The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2017, and provided an update on its clinical and operational activities. Second Quarter 2017 Highlights and Projected Milestones Meropenem-Vaborbactam The Company announced positive results from a planned, interim analysis of the TANGO-2 trial of its fix... 
Printer Friendly Version
07/31/17The Medicines Company to Announce Second-Quarter 2017 Financial Results on August 9
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 31, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, August 9, 2017, at 8:30 a.m., Eastern Daylight Time, to discuss its second-quarter 2017 financial results and operational developments. A live audio webcast of the conference call may be accessed in the Investors section of The Medicines Company website. A replay of the webcast will be available on the web... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.